Prostate Cancer Clinical Trial

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Summary

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

View Full Description

Full Description

This is an open label, multi-center Phase 1 study that will follow a 3 + 3 design of dose-escalating cohorts of single and multiple doses of P-PSMA-101 to determine a Recommended Phase 2 Dose (RP2D). Additional participants will be treated with P-PSMA-101 at the determined RP2D.

Following consent, enrolled participants will undergo a leukapheresis procedure to obtain peripheral blood mononuclear cells (PBMCs) which will be sent to a manufacturing site to produce P-PSMA-101 CAR-T cells. The cells will then be returned to the investigational site and administered after a lymphodepleting chemotherapy regimen. Rimiducid may be administered as indicated.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subjects ≥18 years of age
Must have a confirmed diagnosis of mCRPC or SGC
Must have measurable disease by RECIST 1.1 or bone only metastases with measurable PSA (≥1 ng/mL) (mCRPC subjects only)
Must have progressed by PCWG3 and/or RECIST 1.1 (mCRPC subjects only)
Must be willing to practice birth control from screening and for 2 years after the last administration of P-PSMA-101
Must have adequate vital organ function within pre-determined parameters
Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

Exclusion Criteria:

Has inadequate venous access and/or contraindications to leukapheresis
Has an active second malignancy in addition to mCRPC or SGC, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
Has a history of or active autoimmune disease
Has a history of significant central nervous system (CNS) disease, such as stroke or epilepsy
Has an active systemic (viral, bacterial or fungal) infection
Has received anti-cancer medications (excluding GnRH targeted therapies) within 2 weeks of the time of initiating conditioning chemotherapy
Has received immunosuppressive medications (including anti-cancer medications) within 2 weeks of initiating leukapheresis and/or expected to require them while enrolled in the study
Has received systemic corticosteroid therapy within 2 weeks of either the required leukapheresis or is expected to require it during the course of the study
Has CNS metastases or symptomatic CNS involvement
Has a history of significant ocular disease
Has a history of significant liver disease or active liver disease
Has liver metastases (<5 lesions and maximum diameter <> Has a history of or known predisposition to HLH or MAS

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

60

Study ID:

NCT04249947

Recruitment Status:

Active, not recruiting

Sponsor:

Poseida Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

City of Hope Comprehensive Cancer Center
Duarte California, 91010, United States
University of California San Diego
San Diego California, 92093, United States
University of California San Francisco
San Francisco California, 94143, United States
Sarah Cannon Research Institute at HealthONE
Denver Colorado, 80218, United States
Tulane University Hospital and Clinic
New Orleans Louisiana, 70112, United States
University of Maryland, Baltimore
Baltimore Maryland, 21201, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
Massachusetts General Hospital
Boston Massachusetts, 02215, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Tennessee Oncology
Nashville Tennessee, 37203, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

60

Study ID:

NCT04249947

Recruitment Status:

Active, not recruiting

Sponsor:


Poseida Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.